Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Insurance coverage varies dramatically
Date of publication September 25, 2023 Keyword diabetes blood glucose safety event-driven noninferiority HbA1c cardiovascular outcome trials duration reduce blood glucose stroke world regions double-blind diabetes duration people body weight sites weekly subcutaneous injections primary analysis superior analysis revascularization adverse cardiovascular events type 2 diabetes characteristics weight body baseline characteristics subcutaneous injection peripheral arterial disease disease CV benefits region cardiovascular disease CV death GLP-1 receptor agonists CV disease MACE glucose years type superiority outcome trials comparison CV safety BMI events trials agonists myocardial infarction design outcomes GLP-1 cardiovascular events tirzepatide atherosclerotic cardiovascular disease components of MACE coronary revascularization atherosclerotic CV disease infarction CV outcome trials coronary disease receptor agonists occurrence baseline randomized participants world age death dulaglutide injection artery disease countries participants analysis efficacy evidence benefits primary outcome DOI Identifier PMID: 37758044 DOI: Dimensions ID: pub.1164360511 Resource type Article Rights statement In Copyright License Attribution 4.0 International Journal title American Heart Journal Journal volume 267 Page start 1 Page end 11 Version Publisher Funder Cleveland Clinic American Heart Association John Wiley & Sons (United States) National Health and Medical Research Council MSD (United States) Bristol-Myers Squibb (United States) Chiesi (Italy) AbbVie (United States) AstraZeneca (United States) Mayo Clinic Novartis (United States) Boehringer Ingelheim (United States) United States Department of Veterans Affairs Pfizer (United States) Roche (United States) Abbott (United States) Sanofi (United States) Regeneron (United States) Medtronic (United States) Bayer (United States) International Diabetes Federation Otsuka (United States) Boston Scientific (United States) Eli Lilly (United States) Menarini Group (Italy) American Diabetes Association Amgen (United States) ISSN 0002-8703 1097-6744 Publisher Elsevier Relations Parents: In Collection: This work has no parents.
Treatment can be applied to any area of excess fat on the body, including the face, arms, hips, stomach, neck and thighs
Beyond discomfort, theyre also commonly accompanied by fatigue, dizziness, and nausea, all of which can make it more difficult to sustain longer or higher-intensity efforts
US$ 28.37
US$ 26.71
US$ 28.09
US$ 24.57
